阅读说明：本技术 白头翁皂苷b4在制备降血压药物中的应用 (Application of anemonin B4 in preparation of medicine for lowering blood pressure ) 是由 高红伟 苑仁祎坤 许琼明 杨世林 奉建芳 于 2019-10-31 设计创作，主要内容包括：本发明公开了白头翁皂苷B4在制备降血压药物中的应用。白头翁皂苷B4对高血压具有治疗作用,既能降低肾性高血压的血压,又能降低自发性高血压的血压,并且对高血压具有保护作用和改善心脏功能的作用。(The invention discloses an application of anemonin B4 in preparing a medicine for reducing blood pressure. Pulsatillae saponin B4 has therapeutic effect on hypertension, and has effects of reducing blood pressure of renal hypertension, spontaneous hypertension, protecting hypertension and improving cardiac function.)

1. The anemonin B4 can be used for preparing medicine for lowering blood pressure.

2. The use of anemonin B4 in the preparation of a medicament for lowering blood pressure according to claim 1, wherein the medicament is a medicament for treating renal hypertension.

3. The use of anemonin B4 in the preparation of a medicament for lowering blood pressure according to claim 1, wherein the medicament is a medicament for treating essential hypertension.

Technical Field

The invention relates to the technical field of medicines, in particular to application of anemonin B4 in preparation of a medicine for reducing blood pressure.

Background

Abnormal rise of blood pressure is one of the main risk factors for the occurrence and development of cardiovascular diseases, and long-term rise or instability of blood pressure causes serious damage to target organs such as heart, brain, kidney, blood vessels and the like, thereby seriously affecting the prognosis of the diseases. Therefore, the stabilization of blood pressure, the prevention and improvement of the damage of target organs caused by hypertension are the final objective of the treatment of hypertension. Pulsatillae saponin B4 is pentacyclic triterpenoid saponin extracted from Pulsatilla chinensis (Thunb.) nakai of perennial herb of Ranunculaceae, and has antiinflammatory, antibacterial, immunoregulatory, antitumor, antioxidant and antiviral effects, such as: application of pulsatilla saponin B4 with publication number CN 105213410A as immunomodulator in medicine for treating acute inflammation; the application of the pulsatilla saponin B4 with the publication number of CN 105535004A as an EV71 virus inhibitor in preparing the hand-foot-and-mouth disease resistant medicine is disclosed, but the pulsatilla saponin monomeric compound which has the effect of reducing blood pressure is not reported at present.

Disclosure of Invention

The invention researches the effect of the pulsatilla chinensis saponin B4 in the medicine for treating hypertension from the mechanism of hypertension, and provides scientific basis and experimental basis for preventing and treating hypertension subsequently by pulsatilla chinensis saponin B4.

The invention aims to provide application of anemonin B4 in preparation of a medicine for reducing blood pressure.

Wherein the medicament is a medicament for treating renal hypertension.

Wherein the medicament is a medicament for treating essential hypertension.

The invention at least comprises the following beneficial effects:

pulsatillae saponin B4 has therapeutic effect on hypertension, and has effects of reducing blood pressure of renal hypertension, spontaneous hypertension, protecting hypertension and improving cardiac function.

The pulsatilla saponin B4 is applied to the medicine for treating renal hypertension, can improve the content of Nitric Oxide (NO) in serum, and reduce the content of angiotensin II (Ang II) and Endothelin (ET) in the plasma to improve vasomotor function and reduce blood pressure, and can reduce HW/BW and LVI values of heart, inhibit myocardial hypertrophy, contribute to improving the contraction and relaxation functions of ventricle, and play a role in protecting hypertension and improving heart function.

When the pulsatilla saponin B4 is applied to the medicine for treating the spontaneous hypertension, the Nitric Oxide (NO) content in serum can be increased, the angiotensin II (AngII) content in the plasma can be reduced, the aorta internal diameter can be reduced, and the effects of reducing the blood pressure, protecting the hypertension and improving the cardiac function can be realized.

Experiments in specific embodiments prove the application of the pulsatilla saponin B4 in lowering blood pressure.

Drawings

FIG. 1 is a bar graph of the aortic inner diameters of rats of the blank control group, the model group, the B45 mg/kg group, the B410 mg/kg group, the B420 mg/kg group and the losartan potassium group;

FIG. 2 is a bar graph of the EF values of rats in the blank control group, model group, B45 mg/kg group, B410 mg/kg group, B420 mg/kg group and losartan potassium group;

FIG. 3 is a bar graph of the FS values of rats of the blank control group, the model group, the B45 mg/kg group, the B410 mg/kg group, the B420 mg/kg group and the losartan potassium group.

Detailed Description

The present invention is further described in detail below with reference to examples to enable those skilled in the art to practice the invention with reference to the description.

It will be understood that terms such as "having," "including," and "comprising," as used herein, do not preclude the presence or addition of one or more other elements or groups thereof.

It is to be noted that the experimental methods described in the following embodiments are all conventional methods unless otherwise specified, and the reagents and materials are commercially available unless otherwise specified.

The data obtained by the experiment are subjected to single-factor variance analysis and t test data by adopting STATA8.0 statistical software, the difference is P <0.05, the difference has statistical significance, and the smaller the P, the better the effect is.